➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Harvard Business School
Merck
Johnson and Johnson
McKinsey

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,737,591

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,737,591
Title:Compositions and methods comprising serratia peptidase for inhibition of bacterial vaginosis, bacterial vaginitis or fungal vaginitis
Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.
Inventor(s): Olmstead; Stephen Francis (Reno, NV)
Assignee: PROTHERA, INC. (Reno, NV)
Application Number:13/072,544
Patent Claims:1. A method of inhibiting Gardnerella vaginalis in a mammal, the method comprising: identifying an increased prevalence of Gardnerella vaginalis and a decreased prevalence of the normally predominant Lactobacillus species in said mammal; and orally administering to the mammal a therapeutically effective amount of an enterically coated composition comprising at least one pharmaceutically acceptable carrier, Serratia peptidase, and an a mixture of enzymes consisting of bromelain, papain, nattokinase and lumbrokinase for a time sufficient to cause significant Gardnerella vaginalis reduction within the mammal.

2. The method of claim 1 wherein the method further comprises administering at least one of lactoferrin and a chelating agent in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

3. The method of claim 1 wherein the method further comprises administering at least one of an anti-bacterial vaginosis, bacterial vaginitis or fungal vaginitis acid-stable cellulase or an anti-bacterial vaginosis, bacterial vaginitis or fungal vaginitis anti-polymeric .beta.-1,6-N-acetyl-D-glucosamine (poly-.beta.-1,6-GlcNAc) agent in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

4. The method of claim 1 wherein the method further comprises administering at least one of an acid-stable hemicellulase/pectinase complex, .beta.-gluconase, acid protease, or alkaline protease in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

5. The method of claim 1 wherein the method further comprises administering at least one an acid-stable agent in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal, the at least one agent selected from the following: a disaccharidase; amylase; .alpha.-amylase; .beta.-amylase; glucoamylase; endoglucanase; xylanase; lipase; lysozyme; an enzyme with dipeptidyl peptidase IV (DPP-IV) activity; chitosanase; ficin; kiwi protease; any plant-derived protease or proteinase, or phytase.

6. The method of claim 1 wherein the method further comprises administering at least one an acid-stable enzyme in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal, the at least one enzyme selected from the following: 1,2-1,3-.alpha.-D-mannanmannohydrolase, 1,3-.beta.-D-xylanxylanohydrolase, 1,3-.beta.-D-glucan glucanohydrolase, 1,3(1,3;1,4)-.alpha.-D-glucan 3-glucanohydrolase, 1,3(1,3;1,4)-.beta.-D-glucan 3(4)-glucanohydrolase, 1,3-1,4-.alpha.-D-glucan 4-glucanohydrolase, 1,4-.alpha.-D-glucan glucanehydrolase, 1,4-.alpha.-D-glucan glucohydrolase, 1,4-(1,3:1,4)-.beta.-D-glucan 4-glucanohydrolase, 1,4-.beta.-D-glucan glucohydrolase, 1,4-.beta.-D-xylan xylanohydrolase, 1,4-.beta.-D-mannanmannanohydrolase, 1,5-.alpha.-L-arabinanohydrolase, 1,4-.alpha.-D-glucan maltohydrolase, 1,6-.alpha.-D-glucan 6-glucanohydrolase, 2,6-.beta.-fructan fructanohydrolase, .alpha.-dextrin 6-glucanohydrolase, .alpha.-D-galactoside galactohydrolase, .alpha.-D-glucoside glucohydrolase, .alpha.-D-mannoside mannohydrolase, acylneuraminyl hydrolase, Aerobacter-capsular-polysaccharide galactohydrolase, .beta.-D-fructofuranoside fructohydrolase, .beta.-D-fucoside fucohydrolase, .alpha.-D-fructan fructohydrolase, .beta.-D-galactoside galactohydrolase, .beta.-D-glucoside glucohydrolase, .beta.-D-glucuronoside, glucuronosohydrolase, .beta.-D-mannoside mannohydrolase, .beta.-N-acetyl-D-hexosaminide N-acetylhexosamino hydrolase, cellulose-sulfate sulfohydrolase, collagenase, dextrin 6-.alpha.-D-glucanohydrolase, glycoprotein-phosphatidylinositol phosphatidohydrolase, hyaluronate 4-glycanohydrolase, hyaluronoglucuronidase, pectin pectylhydrolase, peptidoglycan N-acetyl-muramoylhydrolase, phosphatidylcholine 2-acylhydrolase, phosphatidylcholine 1-acylhydrolase, poly(1,4-.alpha.-D-galacturonide), poly(1,4-(N-acetyl-.beta.-D-glucosaminide))glycanohydrolase, proteases, sucrose .alpha.-glucosidase, triacylglycerol acylhydrolase, triacylglycerol protein-acylhydrolase.

7. The method of claim 1 wherein the method further comprises administering at least one of an acid-stable subtilisin and an acid-stable DNAse I in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

8. The method of claim 1 wherein the method further comprises: further identifying the presence of at least one of Clostridium ssp, Klebsiella ssp, Pseudomonas ssp, Bacteroides ssp, Enterococcus ssp, Campylobacter ssp, Bacillus ssp, Yersinia ssp, Brucella ssp, Salmonella ssp, Shigella ssp, Fusobacterium ssp, Spirochaetes ssp, Entamoeba ssp, Candida ssp, Escherichia coli, Vibrio cholerae, Staphylococcus ssp, Streptococcus ssp, Hemophilus ssp, Aspergillus ssp and Gardnerella ssp in the mammal, and administering to the mammal a therapeutically effective amount of the anti-biofilm Serratia peptidase agent for a time sufficient to treat the identified Clostridium ssp, Klebsiella ssp, Pseudomonas ssp, Bacteroides ssp, Enterococcus ssp, Campylobacter ssp, Bacillus ssp, Yersinia ssp, Brucella ssp, Salmonella ssp, Shigella ssp, Fusobacterium ssp, Spirochaetes ssp, Entamoeba ssp, Candida ssp, Escherichia coli, Vibrio cholerae, Staphylococcus ssp, Streptococcus ssp, Hemophilus ssp, Aspergillus ssp and Gardnerella ssp.

9. The method of claim 1 wherein the method further comprises administering a lactoferrin peptide in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

10. The method of claim 1 wherein the method further comprises administering a green tea extract in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal.

11. The method of claim 1 wherein the method further comprises administering in an amount and for a time sufficient to cause significant reduction of the bacterial vaginosis, bacterial vaginitis or fungal vaginitis within of the mammal, a chelating agent selected from the group comprising ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA); the disodium, trisodium, tetrasodium, dipotassium, tripotassium, dilithium and diammonium salts of EDTA; the barium, calcium, cobalt, copper, dysprosium, europium, iron, indium, lanthanum, magnesium, manganese, nickel, samarium, strontium, and zinc chelates of EDTA; trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate; N,N-bis(2-hydroxyethyl)glycine; 1,3-diamino-2-hydroxypropane-N,N,N',N'-tetraacetic acid; 1,3-diaminopropane-N,N,N',N'-tetraacetic acid; ethylenediamine-N,N'-diacetic acid; ethylenediamine-N,N'-dipropionic acid dihydrochloride; ethylenediamine-N,N'-bis(methylenephosphonic acid)hemihydrate; N-(2-hydroxyethyl)ethylene-diamine-N,N',N'-triacetic acid; ethylenediamine-N,N,N',N'-tetrakis(methylenephosphonic acid); 0,0'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid; N,N-bis(2-hydroxybenzyl)ethyl-ene diamine-N,N-diacetic acid; 1,6-hexamethylenediamine-N,N,N',N'-tetraacetic acid; N-(2-hydroxyethyl)iminodiacetic acid; iminodiacetic acid; 1,2-diaminopropane-N,N,N',N'-tetraacetic acid; nitrilotriacetic acid; nitrilotripropionic acid; the trisodium salt of nitrilotris-(methylene-phosphoric acid); 7,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo[11,11,11] pentatriacontane hexahydrobromide; triethylenetetraminie-N,N,N',N'',N''',N'''-hexaacetic acid; deferoxamine; deferiprone; and deferasirox.

12. The method of claim 1 wherein the method further comprises administering an antibiotic in conjunction with the Serratia peptidase, bromelain, papain and a fibrinolytic enzyme, in an amount and for a time sufficient to cause significant biofilm degradation within of the mammal.

13. The method of claim 1 wherein the method further comprises administering an quercetin in conjunction with the Serratia peptidase, bromelain, papain and a fibrinolytic enzyme, in an amount and for a time sufficient to cause significant biofilm degradation within of the mammal.

14. The method of claim 1 wherein the method further comprises administering seaprose in conjunction with the Serratia peptidase, bromelain, papain and a fibrinolytic enzyme, in an amount and for a time sufficient to cause significant biofilm degradation within of the mammal.

15. The method of claim 1 wherein the method further comprises administering Fusarium protease in conjunction with the Serratia peptidase, bromelain, papain and a fibrinolytic enzyme, in an amount and for a time sufficient to cause significant biofilm degradation within of the mammal.

Details for Patent 9,737,591

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial PROTHERA, INC. (Reno, NV) 2029-11-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Baxter
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.